Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Terns Pharmaceuticals ( (TERN) ) has provided an update.
On January 16, 2026, Terns Pharmaceuticals amended its existing Exclusive Option and License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd., under which Hansoh already held exclusive rights to develop and commercialize TERN-701 for oncology indications in mainland China, Taiwan, Hong Kong and Macau. The amendment grants Terns an exclusive, royalty-bearing, sublicensable and perpetual license, outside the Hansoh Territory, to use certain patents and patent applications invented by Hansoh and its affiliate in connection with TERN-701, replacing a previous non-exclusive, non-sublicensable, royalty-free license held by a Terns subsidiary; in return, Terns will pay Hansoh a $1 million upfront fee and low single-digit tiered royalties on net sales of TERN-701 products covered by those patents, strengthening Terns’ global intellectual property position and commercial flexibility for TERN-701 beyond Greater China.
The most recent analyst rating on (TERN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Terns Pharmaceuticals stock, see the TERN Stock Forecast page.
Spark’s Take on TERN Stock
According to Spark, TipRanks’ AI Analyst, TERN is a Neutral.
The score is driven by strong technical momentum and a solid, low-debt balance sheet, partially offset by persistent losses and significant cash burn with no revenue base. Corporate developments are mixed: encouraging TERN-701 trial results and a capital raise that improves funding visibility, but pipeline narrowing and dilution risk temper the outlook. Valuation remains challenging given negative earnings and no dividend support.
To see Spark’s full report on TERN stock, click here.
More about Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing small-molecule therapeutic products for oncology, including the investigational agent TERN-701, with a geographic strategy that differentiates rights between Greater China and the rest of the world.
Average Trading Volume: 4,144,413
Technical Sentiment Signal: Buy
Current Market Cap: $3.89B
For a thorough assessment of TERN stock, go to TipRanks’ Stock Analysis page.